Rigel Pharmaceuticals published final additional follow-up data from the Phase 1/2 ARROW trial of pralsetinib (GAVRETO) in metastatic RET fusion-positive non-small cell lung cancer in the Journal of Clinical Oncology. The updated readout adds 42 months of follow-up to earlier results. In the measurable-disease population (n=259), overall response rate was reported at 70% with 7% complete responses and 63% partial responses. The company also reiterated a manageable safety profile, noting three treatment-related deaths in treatment-naive patients in Asia, with no new safety signals and no hypersensitivity events after prior immunotherapy. Investigators including Justin Gainor of Mass General Brigham highlighted durable responses and response signals in patients with baseline measurable CNS metastases.